We are live on ! Find out more
CATX icon

Perspective Therapeutics

27 hedge funds and large institutions have $3.71M invested in Perspective Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

13% more funds holding

Funds holding: 2427 (+3)

2% more capital invested

Capital invested by funds: $3.65M → $3.71M (+$67.9K)

0.01% less ownership

Funds ownership: 0.79%0.78% (-0.01%)

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
27
Holders Change
+3
Holders Change %
+12.5%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
7
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
26
UBS Group
Switzerland
$4K -$2.83K -296 -41%
JFA
27
JNBA Financial Advisors
Minnesota
$4K
BIM
28
BlackRock Investment Management
Delaware
-$9K -983 Closed

CATX Hedge Fund Activity: Q2 2016 in Review

27 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2016, worth a combined $3.71M — up 1.9% from $3.65M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CATX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 7 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $27K. The largest seller was Citadel Advisors, cutting an estimated $67.2K.

  • 27 institutional investors held Perspective Therapeutics (CATX) as of Q2 2016, up from 24 in Q1 2016.
  • Funds reported $3.71M of Perspective Therapeutics stock for Q2 2016, up 1.9% quarter-over-quarter.
  • 4 funds opened new Perspective Therapeutics positions in Q2 2016 and 1 closed out, a net change of +3 holders.
  • The largest Perspective Therapeutics buyer in Q2 2016 was Susquehanna International Group, an estimated $27K added.
  • The largest Perspective Therapeutics seller in Q2 2016 was Citadel Advisors, an estimated $67.2K sold.

Based on aggregated 13F filings for Q2 2016.